Response Genetics, Inc. to Release Third Quarter Financial Results and Host Conference Call on November 13, 2012

 Response Genetics, Inc. to Release Third Quarter Financial Results and Host
                     Conference Call on November 13, 2012

PR Newswire

LOS ANGELES, Nov. 6, 2012

LOS ANGELES, Nov. 6, 2012 /PRNewswire/ --Response Genetics, Inc. (Nasdaq:
RGDX),a company focused on the development and commercialization of molecular
diagnostic tests for cancer, will announce its third quarter financial results
and give an operational update in a press release to be issued before the
market opens on Tuesday, November 13, 2012. The company will host a conference
call that same day at 10:00 a.m. EST to discuss its financial results.

Conference Call Details

To access the conference call by phone on November 13 at 10:00 a.m. EST, dial
(800) 537-0745 or (253) 237-1142 for international participants. A telephone
replay will be available beginning approximately two hours after the call
through November 20, and may be accessed by dialing (855) 859-2056 or (404)
537-3406. The conference passcode for both the live call and replay is
57580014.

To access the live and archived webcast of the conference call, go to the
Investor Relations section of the Company's website at
http://investor.responsegenetics.com. It is advised that participants connect
at least 15 minutes prior to the call to allow for any software downloads that
might be necessary.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer. The Company's technologies enable extraction and
analysis of genetic information derived from tumor cells stored as
formalin-fixed and paraffin-embedded specimens. The Company's principal
customers include oncologists and pathologists. In addition to diagnostic
testing services, the Company generates revenue from the sale of its
proprietary analytical pharmacogenomic testing services of clinical trial
specimens to the pharmaceutical industry. The Company's headquarters is
located in Los Angeles, California. For more information, please visit
www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties.
Such statements may include, without limitation, statements with respect to
the Company's plans, objectives, projections, expectations and intentions,
such as the ability of the Company, to provide clinical testing services to
the medical community, to continue to strengthen and expand its sales force,
to continue to build its digital pathology initiative, to attract and retain
qualified management, to continue to strengthen marketing capabilities, to
expand the suite of ResponseDX® products, to continue to provide clinical
trial support to pharmaceutical clients, to enter into new collaborations with
pharmaceutical clients, to enter into areas of companion diagnostics, to
continue to execute on its business strategy and operations, to continue to
analyze cancer samples and the potential for using the results of this
research to develop diagnostic tests for cancer, the usefulness of genetic
information to tailor treatment to patients, and other statements identified
by words such as "project," "may," "could," "would," "should," "believe,"
"expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities Exchange
Commission. Actual results, including, without limitation, actual sales
results, if any, or the application of funds, may differ from those set forth
in the forward-looking statements. These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control). The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

Investor Relations Contact: Company Contact:
Peter Rahmer                Thomas A. Bologna
Trout Group                 Chairman & CEO
646-378-2973                323-276-6060

SOURCE Response Genetics, Inc.